US Patent 9758581 Humanized anti-CD4 antibody with immunosuppressive properties
Patent 9758581 was granted and assigned to Biotest AG on September, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+197 characters)
Article
Patent abstract
A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Helmut Jonuleit0
John Wijdenes0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09758581 Humanized anti-CD4 antibody with immunosuppressive properties US Patent 9758581 Humanized anti-CD4 antibody with immunosuppressive properties
Infobox
Patent Number
09758581
Patent Number
9758581
Edits on 14 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09758581 Humanized anti-CD4 antibody with immunosuppressive properties
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09758581
Date of patent
September 12, 2017
Patent application number
14176485
Date Filed
February 10, 2014
Patent primary examiner
Find more entities like US Patent 9758581 Humanized anti-CD4 antibody with immunosuppressive properties
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.